Literature DB >> 2008397

Neuroleptic malignant syndrome. When levodopa withdrawal is the cause.

C Rainer1, N A Scheinost, E J Lefeber.   

Abstract

Neuroleptic malignant syndrome has been described in patients receiving dopamine antagonists and in a few patients after withdrawal of dopaminergic antiparkinson therapy. Complications affect almost all organ systems and can be life-threatening. Most patients have fever, altered level of consciousness, bradykinesia, and rigidity. Treatment includes withdrawal of the causative agent and supportive therapy for complications. When withdrawal of a dopaminergic medication is the suspected cause, the agent should be reinstated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2008397     DOI: 10.1080/00325481.1991.11700900

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  3 in total

1.  Serotonin syndrome caused by a moclobemide-clomipramine interaction.

Authors:  O Spigset; T Mjörndal; O Lövheim
Journal:  BMJ       Date:  1993-01-23

Review 2.  Implications of dopaminergic medication withdrawal in Parkinson's disease.

Authors:  J Koschel; K Ray Chaudhuri; L Tönges; M Thiel; V Raeder; W H Jost
Journal:  J Neural Transm (Vienna)       Date:  2021-07-29       Impact factor: 3.850

Review 3.  Bench-to-bedside review: mechanisms and management of hyperthermia due to toxicity.

Authors:  Florian Eyer; Thomas Zilker
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.